Chemomab Therapeutics (CMMB) Expected to Announce Quarterly Earnings on Thursday

Chemomab Therapeutics (NASDAQ:CMMB) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Chemomab Therapeutics to announce earnings of ($0.04) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.18). On average, analysts expect Chemomab Therapeutics to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chemomab Therapeutics Price Performance

CMMB stock opened at $1.75 on Thursday. The company has a market capitalization of $12.60 million, a P/E ratio of -0.79 and a beta of 0.65. Chemomab Therapeutics has a 12 month low of $1.35 and a 12 month high of $4.12. The firm’s fifty day simple moving average is $1.70 and its 200-day simple moving average is $1.69.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $25.00.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. XTX Topco Ltd acquired a new stake in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned approximately 0.31% of Chemomab Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 46.05% of the stock is owned by institutional investors and hedge funds.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.